We transform the most promising oncology innovations into highly competitive opportunities that benefit patients, researchers, investors, and Ontario's economy. Cancer Breakthroughs. Realized.

About

We know the business of science.

Funds

We bridge the funding gap.

Investment Opportunities

We are the gateway to Ontario's oncology assets.

FACIT Features: Portfolio company KA Imaging launches first-in-human pilot study to test lung screening x-ray

FACIT congratulates portfolio company KA Imaging on significant clinical development milestone.

KA Imaging, a recent Prospects Fund recipient, is partnering with Grand River Hospital to conduct a pilot study on the use of a high-resolution multi-energy digital x-ray imager for patients with lung nodules.


FACIT Welcomes Har Grover and Ken Lawless to the Board

Strategic appointments of seasoned entrepreneurs add expertise and strengthen governance

Both leaders are passionate supporters of the Ontario life science sector, have broad industry experience and decades of work with entrepreneurial ventures.


FACIT Invests in Three Top Ontario Entrepreneur-Teams from Near Record Pool of Applicants

Prospects Oncology Fund seeds developing pipeline of Ontario-based biotech innovations

With an expanding portfolio of breakthrough innovations, FACIT is committed to supporting Ontario entrepreneurs through the latest round of its Prospects Oncology Fund.  


Healthcare Software Start-Up Ziliomics Financed by FACIT

World-leading genomics cloud computing group builds clinical tool for cancer care in Ontario

Derived from a leading oncology bio-computing group and leveraging insights from the world’s largest cancer genomics projects, Ziliomics develops web-based, modular software platforms that help physicians make actionable treatment decisions for patients living with cancer.


FACIT Appoints Biotech Veteran Dr. David O'Neill as President

Entrepreneur adds US oncology management experience to Ontario commercialization.

Dr O’Neill brings two decades of cancer drug development and seed stage investment experience, as well as an extensive business network in pharma and biotech.


OICR Welcomes Former Merck IO Executive as new President

Dr. Laszlo Radvanyi's industry expertise & network aligns well with OICR and FACIT's shared vision.

FACIT looks forward to working with Dr. Radvanyi on translating Ontario’s breakthrough oncology innovations.


Latest Tweet / Follow

Contact Us